Brain Scientific Inc. (BRSF) Poised to Contribute to Mental Health Research; Provides Technology to Map Brain Response to Psychedelic Treatment
- BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration
- Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed
- BRSF’s E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient’s brain activity in a non-intrusive way
Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Biomarkers are essential as they can help improve diagnostic accuracy and thus improve patient outcomes. There are currently 250 biochemical markers about a broad range of the body’s organic systems and how they function, but this approach still remains a challenge for psychiatric disorders. The partnership between Brain Scientific and Ehave is intended to change this (https://nnw.fm/xNLCO).
Mental health disorders are affecting more and more people worldwide — it has been estimated that 51.5 million adults (20.6%) experienced mental illness in 2019 in the US alone (https://nnw.fm/WwSgs). Psychedelic drugs are increasingly becoming part of mainstream psychiatry conversation. A growing body of evidence indicates that they could be effective for treating a range of mental illnesses, especially when coupled with talking therapy (https://nnw.fm/p2GoH). This breakthrough could potentially have profound implications for a space that has seen few pharmacological advancements over recent decades regarding the treatment of mental disorders affecting millions of people around the world, including depression, anxiety, PTSD, addiction, and more. Still, experts caution that more research is needed.
This is where the partnership between Brain Scientific and Ehave can potentially make a difference. The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI and linked data protocols to develop neural net algorithms. As an initial use case, the neural net algorithm would be used to upload an already trained neuronet into a specialized chip, a temporary E-Tattoo, developed by Brain Scientific.
Brain Scientific would also contribute to the collaboration by providing its proprietary data signal acquisition technology, NeuroCap, and NeuroEEG. These devices, designed to collect and read brain activity, would be linked to the Ehave platform. Brain Scientific will also provide the training and support needed to operate the installed equipment, the required software, and hardware and will develop and validate products within three months of receiving any specifications from Ehave.
As part of the MoU, Ehave’s role would be to acquire real-time patients data from Brain Scientific’s NeuroCap and NeuroEEG and transfer it into a cloud. Both Ehave and Brain Scientific will jointly own the data from this collaboration.
In addition, Ehave could seek to leverage its network of partner healthcare providers, including psychiatrists, psychologists, psychotherapists, and general practitioners, to use NeuroCap and NeuroEEG in clinical settings and collect the data about the electrophysiological changes in brain pre, mid and post-psychedelic drug administration.
The collaboration could lead to building or partnering with functional labs where NeuroCap and NeuroEEG devices could be deployed to conduct market studies on consumer behavior and psychology and collect data on various brain-related physiological and mental disorders. These labs are likely to start in Australia and could be rolled out in other parts of the world where Ehave has its footprint.
With E-Tattoo, an EEG device about the size of a stamp, Brain Scientific allows continuous measurement of patients’ brain activity in a non-intrusive way and with minimal distraction from everyday life. Brain Scientific believes that the future of EEG testing will be based on non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. Graphene, often called the wonder material of the 21st century, could potentially allow the development of smaller electrodes — even thinner than a human hair. The two companies are poised to leverage their unique expertise and work together to make a big step forward in neurological and psychiatric research by utilizing graph-based AI and linked data protocols to help develop biomarkers for psychiatric disorders.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration
- Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed
- BRSF’s E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient’s brain activity in a non-intrusive way
Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Biomarkers are essential as they can help improve diagnostic accuracy and thus improve patient outcomes. There are currently 250 biochemical markers about a broad range of the body’s organic systems and how they function, but this approach still remains a challenge for psychiatric disorders. The partnership between Brain Scientific and Ehave is intended to change this (https://nnw.fm/xNLCO).
Mental health disorders are affecting more and more people worldwide — it has been estimated that 51.5 million adults (20.6%) experienced mental illness in 2019 in the US alone (https://nnw.fm/WwSgs). Psychedelic drugs are increasingly becoming part of mainstream psychiatry conversation. A growing body of evidence indicates that they could be effective for treating a range of mental illnesses, especially when coupled with talking therapy (https://nnw.fm/p2GoH). This breakthrough could potentially have profound implications for a space that has seen few pharmacological advancements over recent decades regarding the treatment of mental disorders affecting millions of people around the world, including depression, anxiety, PTSD, addiction, and more. Still, experts caution that more research is needed.
This is where the partnership between Brain Scientific and Ehave can potentially make a difference. The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI and linked data protocols to develop neural net algorithms. As an initial use case, the neural net algorithm would be used to upload an already trained neuronet into a specialized chip, a temporary E-Tattoo, developed by Brain Scientific.
Brain Scientific would also contribute to the collaboration by providing its proprietary data signal acquisition technology, NeuroCap, and NeuroEEG. These devices, designed to collect and read brain activity, would be linked to the Ehave platform. Brain Scientific will also provide the training and support needed to operate the installed equipment, the required software, and hardware and will develop and validate products within three months of receiving any specifications from Ehave.
As part of the MoU, Ehave’s role would be to acquire real-time patients data from Brain Scientific’s NeuroCap and NeuroEEG and transfer it into a cloud. Both Ehave and Brain Scientific will jointly own the data from this collaboration.
In addition, Ehave could seek to leverage its network of partner healthcare providers, including psychiatrists, psychologists, psychotherapists, and general practitioners, to use NeuroCap and NeuroEEG in clinical settings and collect the data about the electrophysiological changes in brain pre, mid and post-psychedelic drug administration.
The collaboration could lead to building or partnering with functional labs where NeuroCap and NeuroEEG devices could be deployed to conduct market studies on consumer behavior and psychology and collect data on various brain-related physiological and mental disorders. These labs are likely to start in Australia and could be rolled out in other parts of the world where Ehave has its footprint.
With E-Tattoo, an EEG device about the size of a stamp, Brain Scientific allows continuous measurement of patients’ brain activity in a non-intrusive way and with minimal distraction from everyday life. Brain Scientific believes that the future of EEG testing will be based on non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. Graphene, often called the wonder material of the 21st century, could potentially allow the development of smaller electrodes — even thinner than a human hair. The two companies are poised to leverage their unique expertise and work together to make a big step forward in neurological and psychiatric research by utilizing graph-based AI and linked data protocols to help develop biomarkers for psychiatric disorders.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
